Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Third Harmonic Bio Inc. (THRD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/04/2025: THRD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -5.85% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 156.96M USD | Price to earnings Ratio - | 1Y Target Price 4.62 |
Price to earnings Ratio - | 1Y Target Price 4.62 | ||
Volume (30-day avg) 365767 | Beta 2.51 | 52 Weeks Range 3.18 - 16.94 | Updated Date 04/6/2025 |
52 Weeks Range 3.18 - 16.94 | Updated Date 04/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.09 |
Earnings Date
Report Date 2025-03-27 | When - | Estimate -0.33 | Actual -0.29 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -12.86% | Return on Equity (TTM) -16.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -124442393 | Price to Sales(TTM) - |
Enterprise Value -124442393 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.09 | Shares Outstanding 45103900 | Shares Floating 13024653 |
Shares Outstanding 45103900 | Shares Floating 13024653 | ||
Percent Insiders 9.12 | Percent Institutions 100.56 |
Analyst Ratings
Rating 4.33 | Target Price 19 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Third Harmonic Bio Inc.
Company Overview
History and Background
Third Harmonic Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a highly selective, oral therapy, donemirsen, for the treatment of severe allergic diseases. Founded in 2019, they went public in 2022. They were later acquired by Synageva Biopharma Corp. in 2024.
Core Business Areas
- Pharmaceutical Development: Focused on developing and commercializing donemirsen for allergic diseases.
Leadership and Structure
The leadership team included key executives in research and development, clinical operations, and business development. Information regarding the organizational structure is limited as they were acquired.
Top Products and Market Share
Key Offerings
- Donemirsen: Donemirsen is an oral small molecule inhibitor of the histamine H1 receptor being developed for chronic urticaria. It was the sole drug in Third Harmonic Bio's pipeline. Competing products include antihistamines and biologics like Xolair.
Market Dynamics
Industry Overview
The pharmaceutical industry focused on allergic diseases is competitive, with established players and emerging biotech companies. The market is driven by a growing prevalence of allergic conditions and increasing demand for effective treatments.
Positioning
Third Harmonic Bio aimed to differentiate itself with an oral, selective H1 receptor inhibitor. The oral route of administration and the high selectivity of donemirsen were hoped to be advantageous.
Total Addressable Market (TAM)
The total addressable market for allergic disease treatments is substantial, estimated to be in the billions of dollars. Third Harmonic Bio targeted a specific segment of this market.
Upturn SWOT Analysis
Strengths
- Novel Oral H1 Inhibitor
- Experienced Management Team
- Targeted Market Focus
- Acquired by Synageva for future product developement.
Weaknesses
- Single Product Pipeline
- Clinical Trial Risks
- Reliance on Regulatory Approvals
- Limited Commercial Infrastructure
Opportunities
- Expanding Allergic Disease Market
- Potential for Combination Therapies
- Partnerships with Larger Pharma Companies
- Further Development for Other Allergic Indications
Threats
- Competition from Established Therapies
- Clinical Trial Failures
- Regulatory Hurdles
- Generic Entry of Antihistamines
Competitors and Market Share
Key Competitors
- SNY
- NVS
- TEVA
- LLY
Competitive Landscape
Third Harmonic Bio aimed to compete through product differentiation with an oral selective H1 receptor antagonist.
Major Acquisitions
Synageva Biopharma Corp.
- Year: 2024
- Acquisition Price (USD millions):
- Strategic Rationale: Synageva Biopharma Corp. acquired Third Harmonic Bio to develop and commercialize donemirsen.
Growth Trajectory and Initiatives
Historical Growth: Historical growth was measured by the progression of clinical trials for donemirsen.
Future Projections: Future growth depended on the successful development and commercialization of donemirsen by Synageva Biopharma Corp.
Recent Initiatives: Recent initiatives focused on clinical trial execution and regulatory interactions.
Summary
Third Harmonic Bio was a clinical-stage biopharmaceutical company developing a novel oral therapy for allergic diseases. Its primary strength was its lead drug candidate, donemirsen. The company's weaknesses included a single-product pipeline and clinical trial risks. The acquisition of Third Harmonic Bio by Synageva Biopharma Corp. demonstrates the potential of donemirsen.
Similar Companies
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
NVS
Novartis AG ADR
NVS
Novartis AG ADR
SNY
Sanofi ADR
SNY
Sanofi ADR
TEVA
Teva Pharma Industries Ltd ADR
TEVA
Teva Pharma Industries Ltd ADR
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- News articles
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is approximate and based on available information. The company was acquired.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Third Harmonic Bio Inc.
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 2022-09-14 | CEO & Director Ms. Natalie C. Holles | ||
Sector Healthcare | Industry Biotechnology | Full time employees 53 | Website https://www.thirdharmonicbio.com |
Full time employees 53 | Website https://www.thirdharmonicbio.com | ||
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is also developing THB335, which is in phase 1 clinical trial, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated inflammatory diseases, respiratory, and gastrointestinal conditions. It has a license agreement with Novartis International Pharmaceutical Ltd. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.